STOCK TITAN
  1. Home
  2. News
  3. BRTX

Biorestorative Therapies Inc Stock Price, News & Analysis

BRTX Nasdaq

Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.

BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.

Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.

Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.

Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.

News

BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

Rhea-AI Summary

BioRestorative Therapies (NASDAQ:BRTX) reported its Q2 2025 financial results and business updates. The company achieved revenues of $303,000, marking a 240% increase from Q2 2024, primarily from BioCosmeceutical sales. The quarter ended with a net loss of $2.7 million ($0.30 per share), improved from a $4.0 million loss in Q2 2024.

Key developments include promising preliminary data from the BRTX-100 Phase 2 clinical trial for chronic lumbar disc disease, showing >50% improvement in both ODI and VAS metrics. The company maintains a strong financial position with $7.4 million in cash and investments with no debt. Additionally, BRTX announced a $2 million stock repurchase program through June 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
earnings
-
News

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

Rhea-AI Summary

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET to discuss the results and provide business updates. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 436077. The call will be available for replay on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences earnings
-
News

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

Rhea-AI Summary
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced that CEO Lance Alstodt will be interviewed on the Benzinga All-Access Show on June 18, 2025, at 10:50 a.m. Eastern time. During the interview, the company plans to discuss BRTX-100 clinical data, leadership changes, and strategic updates. The interview will be accessible via live webcast and will later be archived on the company's website in the Investors section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences clinical trial
News

BioRestorative Announces Share Repurchase Program

Rhea-AI Summary
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company, has announced a $2 million share repurchase program effective through June 16, 2026. The company's Board of Directors authorized the buyback program, allowing management to repurchase shares through open market transactions or private negotiations. CEO Lance Alstodt expressed confidence in the company's clinical development pipeline and stated that the current share price does not reflect BioRestorative's intrinsic value. The timing, volume, and value of repurchases will be determined by management based on market conditions and other factors, with flexibility to modify or terminate the program at their discretion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
buybacks
-
News

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

Rhea-AI Summary
BioRestorative Therapies (NASDAQ: BRTX) presented promising preliminary data from its Phase 2 clinical trial of BRTX-100, an FDA fast-tracked autologous stem cell therapy for chronic lumbar disc disease (cLDD). The data, presented at ISSCR 2025, showed over 74% of subjects achieved >50% improvement in function and 72% reported >50% pain reduction by week 52. The trial has expanded from 15 to 36 subjects, progressing toward full enrollment of 99 participants. The therapy demonstrated an excellent safety profile with no serious adverse events reported between 26-104 weeks at the target dose. The FDA requires >30% improvement in function (ODI) and pain reduction (VAS) for trial continuation and BLA approval. The results consistently exceeded these thresholds, showing strengthening efficacy markers with each new data analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16%
Tags
fda approval
-
News

BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

Rhea-AI Summary
BioRestorative Therapies (NASDAQ:BRTX) has appointed Sandy Lipkins as a key executive focused on technology commercialization and business development, effective June 9, 2025. Lipkins brings over 30 years of venture capital, finance, and sales experience, with particular expertise in anti-aging and wellness sectors. His responsibilities will include managing strategic alliances and licensing agreements both domestically and internationally. Lipkins has a strong track record in stem cells, regenerative medicine, and tissue banking, along with experience in scaling companies and biologics manufacturing. CEO Lance Alstodt emphasized how Lipkins' expertise aligns with BRTX's mission to advance their clinical pipeline and expand their BioCosmeceuticals platform. The appointment represents a strategic move to accelerate growth and expand market presence in regenerative medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

Rhea-AI Summary
BioRestorative Therapies (NASDAQ: BRTX) announced it will present new preliminary Phase 2 clinical data for BRTX-100, its stem cell therapy for chronic lumbar disc disease, at ISSCR 2025 in Hong Kong. The presentation will reveal blinded safety and efficacy data from 30 patients on June 13, 2025. BRTX-100, the company's lead candidate, is an autologous mesenchymal stem cell therapy targeting areas with limited blood flow. The Phase 2 trial is a randomized, double-blinded, placebo-controlled study across 16 U.S. sites, enrolling 99 patients in a 2:1 ratio of treatment to placebo. CEO Lance Alstodt highlighted strong signals in both safety and functional improvement. The company will release detailed data via press release before market open on June 13th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences clinical trial
-
News

BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

Rhea-AI Summary
BioRestorative Therapies (NASDAQ:BRTX) has reported its Q1 2025 financial results and provided significant clinical updates. The company's BRTX-100 program achieved major milestones, including FDA Fast Track designation for chronic lumbar disc disease (cLDD) treatment and IND clearance for chronic cervical discogenic pain. Preliminary clinical data from the Phase 2 trial showed positive safety profiles and efficacy trends. Financial results showed revenues of $25,000 (down from $35,000 in Q1 2024), with a net loss of $5.3 million ($0.64 per share). The company maintains a strong financial position with $9.1 million in cash and equivalents, with no outstanding debt. In their metabolic program, BioRestorative received a European patent allowance for their ThermoStem® platform and continues discussions regarding potential licensing agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
earnings
-
News

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

Rhea-AI Summary
BioRestorative Therapies (NASDAQ:BRTX) has reported encouraging preliminary data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease (cLDD). The data, presented at the ISCT 2025 Annual Meeting, shows no serious adverse events (SAEs) and no dose-limiting toxicity at 26-104 weeks with 40X106 cells. The trial is demonstrating positive efficacy trends, exceeding the FDA's requirement of >30% improvement in both Oswestry Disability Index (ODI) and Visual Analog Scale (VAS). Notably, the percentage of subjects achieving >50% improvement in both ODI and VAS increased significantly from 0% at week 2 to 70% at week 52, maintaining at 66.66% through week 104, indicating strong and sustained therapeutic effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
clinical trial
News

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

Rhea-AI Summary

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced it will release its Q1 2025 financial results on Wednesday, May 14, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET to discuss the financial results and provide a business update. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 924151. The call will be broadcast live and archived on the company's website in the Investors section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences earnings

FAQ

What is the current stock price of Biorestorative Therapies (BRTX)?

The current stock price of Biorestorative Therapies (BRTX) is $1.484 as of August 20, 2025.

What is the market cap of Biorestorative Therapies (BRTX)?

The market cap of Biorestorative Therapies (BRTX) is approximately 12.3M.
Stock BRTX logo
Biorestorative Therapies Inc

Nasdaq:BRTX

BRTX Rankings

#5933 Ranked by Market Cap
N/A Ranked by Dividends

BRTX Stock Data

12.29M
6.06M
24.02%
8.77%
2.07%
Biotechnology
Services-misc Health & Allied Services, Nec
Link
United States
MELVILLE